Join us for STI Engage 2025, the country’s leading annual conference for those working to address the STI epidemic. Professionals from public health, clinics, community organizations and beyond will come together for insightful sessions, keynote talks and opportunities to share strategies, strengthen partnerships and drive progress. In this 90-minute interactive workshop, we will focus on a practical introduction to molecular testing (“PCR 101”), a moderated panel discussion and moderated, case-based exercises exploring real-world implementation of molecular point-of-care and central lab collaboration in STI care. #STIEngage
Roche Diagnostics USA
Biotechnology Research
Indianapolis, Indiana 97,224 followers
We're passionate about transforming healthcare by delivering novel diagnostic solutions to help improve patients' lives.
About us
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche Diagnostics is the world leader in in-vitro diagnostics. Working at Roche means working at the forefront of innovation. Our cutting-edge technologies and healthcare solutions were occasionally developed with unconventional methods but always with the highest standard of quality in mind. Our Roche Diagnostics USA offices are located in: • Boston (MA) • Branchburg (NJ) • Indianapolis (IN) • Pleasanton (CA) • Santa Clara (CA) • San Jose (CA) • Seattle (WA) • Tucson (AZ) Follow our page to be kept up to date with news about Roche Diagnostics in the U.S.! Visit our Careers website to view our current openings: www.roche.com/careers
- Website
-
https://usdiagnostics.roche.com
External link for Roche Diagnostics USA
- Industry
- Biotechnology Research
- Company size
- 5,001-10,000 employees
- Headquarters
- Indianapolis, Indiana
- Founded
- 1896
- Specialties
- in-vitro, Biotechnology, Molecular Sequencing, biotech, molecular, and sequencing
Updates
-
Today is World Preeclampsia Day — a reminder that this serious pregnancy complication affects one in seven hospital deliveries in the U.S. and remains a leading cause of maternal and infant morbidity and mortality. Early detection is key, but so is listening to women when they raise concerns. Too often, symptoms are dismissed until it's too late. We’re committed to supporting better clinical decisions by combining test results with patient experiences. Together, we can drive better outcomes through awareness, smarter risk assessment and by amplifying the voices of those most impacted. https://lnkd.in/gHzwJE68
-
Each year, we are proud to take part in the Roche Children's Walk, inspired by and in partnership with Jameson Camp. Jameson Camp is a nonprofit organization based in Indianapolis, committed to empowering youth through meaningful, healthy experiences in nature. #WeAreRoche #RocheChildrensWalk #RocheGivesBack
-
Roche has received FDA approval for the VENTANA MET (SP44) RxDx Assay as the first companion diagnostic to identify non-small cell lung cancer patients eligible for treatment with EMRELIS™. Learn more: https://lnkd.in/gVqCqP-N #cancer #diagnostics
-
-
Today we announced plans to expand our Indianapolis campus — a major investment in our future and our communities. A key part of this growth includes localizing continuous glucose monitoring production — enhancing access to innovative diabetes care solutions for patients across the U.S. and around the world. This means faster delivery, more reliable support and increased availability of life-changing technology. To read our full press release: https://lnkd.in/gR8gsteE #WeAreRoche
-
-
NEW: Today we’re announcing plans to invest up to $550 million in our Diagnostics facility in Indianapolis by 2030, further strengthening our U.S. manufacturing footprint and supporting the production of our continuous glucose monitoring (CGM) technology. This will establish the site as a central hub for CGM manufacturing, creating hundreds of new jobs and enhancing domestic production capabilities. This initiative is a key part of Roche’s broader strategic commitment in pharmaceuticals and diagnostics in the U.S. over the next five years. Indianapolis will become the second global manufacturing site – following Mannheim, Germany – for the production of our CGM solution, underscoring the city’s importance in our global network. Read our full media release: https://lnkd.in/gCgR2QtP
-
-
We’re proud to share that Roche Indianapolis has been recognized by the Indiana Department of Labor / Indiana Occupational Safety and Health Administration (OSHA) as a participant in the Voluntary Protection Program (VPP). VPP is a unique partnership between the Indiana OSHA and private employers like Roche. The program is designed to elevate safety standards by encouraging transparent, collaborative evaluation of workplace safety. This recognition follows years of dedication since the initiative began in 2018, culminating in a comprehensive, week-long onsite evaluation by auditors. With over 500 employees attending the celebration on our campus, this recognition marks a significant achievement in workplace health and safety. Thank you to everyone who helped make this achievement possible. #WorkplaceSafety #OSHA #WeAreRoche
-
-
We’re committed to developing innovative biomarker tests that can help clinicians accurately diagnose neurological disorders and guide treatment. In this Q&A, Maria-Magdalena Patru, M.D., Ph.D., scientific partner, CNS, and Margherita Carboni, Ph.D., indication lead, Neurology, discuss our biomarker assay development and their perspectives on the evolving field of Alzheimer’s diagnostics. Read more: https://lnkd.in/gTM-SwZh #Alzheimers #Diagnostics
-
We’re proud to share that Roche has received FDA Breakthrough Device Designation for the VENTANA® TROP2 (EPR20043) RxDx Device — the first AI-driven companion diagnostic for non-small cell lung cancer (NSCLC). This cutting-edge device combines immunohistochemistry (IHC) with AI-powered image analysis to deliver a level of diagnostic precision beyond what’s possible with manual methods. By integrating Roche’s digital pathology expertise and AstraZeneca’s Quantitative Continuous Scoring platform, we’re setting a new standard for computational pathology and reinforcing our commitment to innovation in oncology diagnostics. 🔬 AI + pathology = a leap forward in treatment decisions 📌 First AI-based CDx device to receive this FDA designation 🎯 Designed to support more precise, tailored therapies for patients with NSCLC Read the full release: https://lnkd.in/gubbvDP3 #Diagnostics #FDA #LungCancer
-
-
We had an impactful week at the National HPV Conference in Indianapolis. It was a valuable opportunity to explore the latest science and best practices around increasing HPV vaccination rates, advancing cervical-cancer screening programs and raising awareness of HPV-related cancers. The conference had a strong, patient-centered focus, with powerful survivor stories and real-world examples highlighting the impact of HPV on individuals and communities. We were proud to host a symposium featuring insights from a cervical-cancer survivor, a pathologist and a lab leader. The panelists offered candid perspectives on the systemic, clinical and patient-level changes needed to successfully implement HPV Self-Collection. To wrap up the week, we welcomed leaders from Cervivor, Inc., American Cancer Society and the American Cancer Society Cancer Action Network (ACS CAN) to our Indianapolis headquarters. We had meaningful conversations around continued collaboration in our shared goal of eliminating cervical cancer. #NHPVC2025
-